13 pages · 20 min read · PDF download
Edward Hawley-Jones
Clinical Safety Officer, iQ HealthTech
White paper
Assessing Clinical Safety in SACT ePMA
How iQemo v1.16.2 compares with the UK SACT Board safety standard
Clinical safety is central to the safe use of electronic prescribing and medicines administration in systemic anti-cancer therapy. This paper examines how iQemo v1.16.2 compares with the UK SACT Board standard for safer ePMA, providing a detailed assessment of clinical controls, responsibilities and areas requiring ongoing assurance.
Download the paper to explore the findings and understand how clinical safety depends not only on product capability, but also on configuration, governance, local workflows and ongoing risk management.
What you will discover
How iQemo compares with the UK SACT Board standard
A clause by clause assessment of all 137 requirements, recording where the standard is met, where support is partial and where it is not met, with the reasoning behind each response.
Where clinical safety responsibilities sit
An examination of the shared responsibilities between the ePMA supplier and healthcare organisation, including the role of DCB0129 and DCB0160 in clinical risk management.
What clinical safety looks like beyond go live
Practical considerations for configuration, connected systems, clinical workflows, change management, and post deployment monitoring to support ongoing assurance.